US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

40.98

-2.8400-6.48%

Pre-market: 40.76-0.2162-0.53%07:14 EDT

Volume:1.80M

Turnover:74.87M

Market Cap:5.51B

PE:-11.77

High:43.38

Open:43.18

Low:40.85

Close:43.82

52wk High:49.70

52wk Low:8.70

Shares:134.37M

Float Shares:131.11M

Volume Ratio:1.22

T/O Rate:1.38%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4823

EPS(LYR):-2.0600

ROE:-64.09%

ROA:-20.64%

PB:5.99

PE(LYR):-19.89

Loading ...

Overview Company News Filings

Definium Therapeutics Shares Jump 22% Premarket After Co's Anxiety Disorder Drug Meets Late-Stage Trial Goal

THOMSON REUTERS

Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo

MT Newswires Live

Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 Odt in Generalized Anxiety Disorder

THOMSON REUTERS

Definium Therapeutics: Phase 3 Voyage Study of DT120 Odt Met Primary & Key Secondary Efficacy Endpoints

THOMSON REUTERS

Definium Therapeutics: Participants on DT120 Odt Achieved Statistically Significant Reduction in Hamilton Anxiety Rating Scale Score

THOMSON REUTERS

Definium Says LSD-Based Pill Reduces Anxiety in Late-Stage Study

Definium Therapeutics: DT120 Odt Generally Well Tolerated in Study, no New Safety Signals Including no Suicidality Signal

THOMSON REUTERS

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)

Definium Therapeutics (DFTX) Is Up 6.0% After Strong DT120 Data Amid Wider Q2 Net Loss

Simply Wall St.

Definium Therapeutics: Buy Rating Reiterated on Strong Clinical and Financial Positioning; $74 Price Target Maintained

Definium Therapeutics (DFTX) Gets a Buy from Jefferies

Definium Therapeutics Price Target Raised to $75.00/Share from $73.00 by Piper Sandler

Ami Fadia Reiterates Buy on Definium Therapeutics, Keeps $50 Price Target Ahead of Key GAD Phase 3 Readouts

Definium Therapeutics Posts Strong Phase 3 Data and Capital Raise to Fund Psychedelic Pipeline

Earnings Flash (DFTX) Definium Therapeutics Posts Q2 EPS -$1.44, vs. FactSet Est of -$0.54

MT Newswires Live

Definium Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)

Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/DFTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":40.98,"timestamp":1787947200000,"preClose":43.82,"halted":0,"volume":1803227,"hourTrading":{"tag":"盘前","latestPrice":40.7638,"preClose":40.98,"latestTime":"07:14 EDT","volume":1151,"amount":46728.934503000004,"timestamp":1788174858670,"change":-0.2162,"changeRate":-0.005276,"amplitude":0.016593},"delay":0,"changeRate":-0.0648105887722502,"floatShares":131114280,"shares":134366950,"eps":-3.482311,"marketStatus":"Pre-Mkt","change":-2.84,"latestTime":"08-31 07:15:05 EDT","open":43.18,"high":43.3799,"low":40.851,"amount":74871849.576718,"amplitude":0.057711,"askPrice":40.98,"askSize":40,"bidPrice":40,"bidSize":103,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788183000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":40.98,"preHourTrading":{"tag":"盘前","latestPrice":40.7638,"preClose":40.98,"latestTime":"07:14 EDT","volume":1151,"amount":46728.934503000004,"timestamp":1788174858670,"change":-0.2162,"changeRate":-0.005276,"amplitude":0.016593},"postHourTrading":{"tag":"盘后","latestPrice":41.13,"preClose":40.98,"latestTime":"19:58 EDT","volume":21808,"amount":893840.7733,"timestamp":1787961509450,"change":0.15,"changeRate":0.00366,"amplitude":0.007565},"volumeRatio":1.22329141949851,"impliedVol":0.8075,"impliedVolPercentile":0.2065},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":131114280,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":1.22329141949851,"shares":134366950,"dividePrice":0,"high":43.3799,"amplitude":0.057711,"preClose":43.82,"low":40.851,"week52Low":8.7,"pbRate":"5.99","week52High":49.7,"institutionHeld":0,"latestPrice":40.98,"committee":0.440559,"eps":-3.482311,"divideRate":0,"volume":1803227,"delay":0,"ttmEps":-3.482311,"open":43.18,"prevYearClose":13.39,"prevWeekClose":40.98,"prevMonthClose":43.52,"prevQuarterClose":47.04,"fiveDayClose":44.91,"twentyDayClose":43.52,"sixtyDayClose":23.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787025600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-08-28","current":-11.768047,"percent":0.25974,"low":-27.074722,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"high":-8.802064,"avg":-13.888901,"sd":5.552967,"marketCap":5887959749},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530},{"date":"2026-08-28","current":-16.642763,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"marketCap":5887959749}],"updateTime":1788174905408},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658260974","title":"Definium Therapeutics Shares Jump 22% Premarket After Co's Anxiety Disorder Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2658260974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658260974?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:44","pubTimestamp":1786535091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974229","title":"Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974229","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974229?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:43","pubTimestamp":1786534989,"startTime":"0","endTime":"0","summary":"Definium Therapeutics  said Wednesday its phase 3 Voyage study of DT120 lysergide orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.The treatment produced an 11.6-point LS mean reduction in HAM-A score at Week 12, compared with 6.2 points for placebo, for a placebo-adjusted difference of 5.4 points , it said.Definium said efficacy was observed as early as Day 2 and sustained through Week 12. DT120 was generally well tolerated, with no new safety signals reported, it added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658747529","title":"Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658747529","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658747529?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:42","pubTimestamp":1786534920,"startTime":"0","endTime":"0","summary":"Definium Therapeutics said a late-stage trial of its treatment for generalized anxiety disorder met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement compared with placebo.The biopharmaceutical company on Wednesday said the results mark the second positive late-stage trial readout for the treatment, DT120, which was previously found to help manage major depressive disorder.DT120 was generally well tolerated in the recent Voyage study, and no new safety signals were identified.\"The unprecedented efficacy demonstrated in Voyage should raise the bar for what patients and clinicians expect from GAD treatments and reinforces our belief that DT120 has the potential to redefine care for the millions of patients in need,\" Chief Executive Rob Barrow said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971877","title":"Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 Odt in Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971877?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA9MXCB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979772","title":"Definium Therapeutics: Phase 3 Voyage Study of DT120 Odt Met Primary & Key Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979772?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nP8N3LD0LZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979085","title":"Definium Therapeutics: Participants on DT120 Odt Achieved Statistically Significant Reduction in Hamilton Anxiety Rating Scale Score","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979085?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nP8N3LD0LZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979053","title":"Definium Says LSD-Based Pill Reduces Anxiety in Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979053","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979053?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":"Definium says LSD-based pill reduces anxiety in late-stage studyAug 12 (Reuters)-Definium TherapeuticsDFTX.Osaid on Wednesday its LSD-based experimental pill significantly reduced anxiety symptoms in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N448178:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658797079","title":"Definium Therapeutics: DT120 Odt Generally Well Tolerated in Study, no New Safety Signals Including no Suicidality Signal","url":"https://stock-news.laohu8.com/highlight/detail?id=2658797079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658797079?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nP8N3LD0LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979766","title":"NASDAQ Trade Halt Halt News Pending at 06:55 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979766","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979766?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:55","pubTimestamp":1786532100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 06:55 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nAQN2MEA26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939053","title":"Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939053?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:45","pubTimestamp":1786365954,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst maintained a Buy rating on Definium Therapeutics today and set a price target of $53.00. In a report released on August 7, Jef...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-its-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-its-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658676240","title":"Definium Therapeutics (DFTX) Is Up 6.0% After Strong DT120 Data Amid Wider Q2 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658676240","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658676240?lang=en_us&edition=fundamental","pubTime":"2026-08-09 07:26","pubTimestamp":1786231608,"startTime":"0","endTime":"0","summary":"In the past week, Definium Therapeutics, Inc. reported a wider Q2 2026 net loss of US$158.99 million with basic and diluted loss per share of US$1.44, while also highlighting strong Phase III DT120 ODT data in major depressive disorder and progress toward pivotal generalized anxiety disorder readouts.\nThe company also released a large real‑world claims analysis showing high discontinuation and switching rates in generalized anxiety disorder treatment, underscoring substantial unmet need that...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-dftx-is-up-60-after-strong-dt120-data","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-dftx-is-up-60-after-strong-dt120-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657716621","title":"Definium Therapeutics: Buy Rating Reiterated on Strong Clinical and Financial Positioning; $74 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2657716621","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657716621?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:55","pubTimestamp":1786143329,"startTime":"0","endTime":"0","summary":"Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Definium Therapeutics. The associated price target remains the same with $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-on-strong-clinical-and-financial-positioning-74-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-on-strong-clinical-and-financial-positioning-74-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657230536","title":"Definium Therapeutics (DFTX) Gets a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2657230536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657230536?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:16","pubTimestamp":1786130179,"startTime":"0","endTime":"0","summary":"Jefferies analyst Andrew Tsai maintained a Buy rating on Definium Therapeutics today and set a price target of $65.00. According to TipRanks, Tsai ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/definium-therapeutics-dftx-gets-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/definium-therapeutics-dftx-gets-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628806","title":"Definium Therapeutics Price Target Raised to $75.00/Share from $73.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628806","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628806?lang=en_us&edition=fundamental","pubTime":"2026-08-08 01:12","pubTimestamp":1786122720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660316","title":"Ami Fadia Reiterates Buy on Definium Therapeutics, Keeps $50 Price Target Ahead of Key GAD Phase 3 Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660316","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657660316?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:35","pubTimestamp":1786066526,"startTime":"0","endTime":"0","summary":"Analyst Ami Fadia from Needham reiterated a Buy rating on Definium Therapeutics and keeping the price target at $50.00. Ami Fadia has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/ami-fadia-reiterates-buy-on-definium-therapeutics-keeps-50-price-target-ahead-of-key-gad-phase-3-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/ami-fadia-reiterates-buy-on-definium-therapeutics-keeps-50-price-target-ahead-of-key-gad-phase-3-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645256","title":"Definium Therapeutics Posts Strong Phase 3 Data and Capital Raise to Fund Psychedelic Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645256","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645256?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:33","pubTimestamp":1786059234,"startTime":"0","endTime":"0","summary":"Definium Therapeutics ( ($DFTX) ) just unveiled an announcement. Definium Therapeutics reported that its Phase 3 Emerge trial of DT120 ODT in major...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-posts-strong-phase-3-data-and-capital-raise-to-fund-psychedelic-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-posts-strong-phase-3-data-and-capital-raise-to-fund-psychedelic-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657966523","title":"Earnings Flash (DFTX) Definium Therapeutics Posts Q2 EPS -$1.44, vs. FactSet Est of -$0.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2657966523","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657966523?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:09","pubTimestamp":1786050595,"startTime":"0","endTime":"0","summary":"Earnings Flash (DFTX) Definium Therapeutics Posts Q2 EPS -$1.44, vs. FactSet Est of -$0.54","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663039","title":"Definium Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663039","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663039?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050110,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryDefinium Therapeutics IncDFTX.OQreported a quarterly adjusted loss of $1.44 per share for the quarter ended Ju","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433EE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502456","title":"Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502456?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047479,"startTime":"0","endTime":"0","summary":"of June 30, 2026, Definium Therapeutics (DFTX) had cash, cash equivalents and investments of approximately $1.1 billion compared to $411.6 million ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-reports-q2-eps-1-44-consensus-53c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-reports-q2-eps-1-44-consensus-53c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650957","title":"Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650957","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650957?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047436,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Q2 net loss widens on higher warrant costsOverviewUS biopharma firm's Q2 net loss widens, driven by higher warrant liabilities and expensesCompany raised $805 mln in public offer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00BJJMRZ35.SGD","VTVT","LU0109394709.USD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD","BK4007","IBRN","IE00B2B36J28.USD","IE0009355771.USD","DFTX","PRAX","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","DTIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}